Mutations in SF3B1 are found predominately in blood cancers, including chronic lymphocytic leukaemia (Liu et al., 2020), MDS (Singh et al., 2020), and both secondary and de novo acute myeloid leukaemia (AML) (Bamopoulos et al., 2020), but also in solid tumours, including melanomas (Nassar and Tan, 2020) and breast cancer (Fu et al., 2017). This evidence concerns the gene SF3B1 and myelodysplastic syndrome.